FDA advisors say no to MDMA. What’s the impact? With Josh Hardman
Business Trip
Challenges in Treatment Rollout: A Controlled Approach and Reimbursement Concerns
This chapter explores the careful strategy required for the introduction of a new treatment following FDA discussions, emphasizing the anticipated challenges in drug delivery and potential hesitancy from insurance providers. The conversation highlights concerns about costs and the necessity for robust evidence, predicting a trend towards stricter regulations and gradual adoption in healthcare environments.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
